The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04311502
Recruitment Status : Active, not recruiting
First Posted : March 17, 2020
Last Update Posted : September 11, 2023
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
The purpose of this study is to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with CFZ loading dose versus 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB).

Condition or disease Intervention/treatment Phase
HIV Tuberculosis Drug: Clofazimine (CFZ) Drug: Rifapentine (RPT) Drug: Isoniazid (INH) Drug: Pyrazinamide (PZA) Drug: Ethambutol (EMB) Drug: Rifampicin (RIF) Dietary Supplement: Pyridoxine (vitamin B6) Phase 2

Detailed Description:

This study will compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with CFZ loading dose versus 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB).

Randomization will be stratified based on HIV status and the presence of advanced disease as determined by chest X-ray.

Participants will be randomized to one of three arms:

  • Arm 1 (Experimental): rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + CFZ 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks
  • Arm 2 (SOC): rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks
  • Arm C (Pharmacokinetic [PK]-only subgroup): PHZE + CFZ 100 mg once daily for 4 weeks; then remain on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks)

All participants must receive pyridoxine (vitamin B6) with each dose of isoniazid (INH) based on current local, national or international dosing guidelines.

Arm 1 participants will be treated for 13 weeks (including a 2-week CFZ loading dose of 300 mg daily). Arm 2 participants will be treated for 26 weeks, and Arm C participants will be treated for 4 weeks.

All participants in Arms 1, 2, and C will be followed from randomization to Week 65. Study visits may include physical examinations; blood, urine, and/or sputum collection; chest X-rays; and electrocardiograms (ECG).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
Actual Study Start Date : June 16, 2021
Estimated Primary Completion Date : June 23, 2024
Estimated Study Completion Date : June 23, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Rifapentine

Arm Intervention/treatment
Experimental: Arm 1: Experimental 3-month, with CFZ loading dose
Participants will receive rifapentine/isoniazid/pyrazinamide/ethambutol (PHZE) + clofazimine (CFZ) 300 mg once daily for 2 weeks; then PHZE + CFZ 100 mg once daily for 6 weeks; then rifapentine/isoniazid/pyrazinamide (PHZ) + CFZ 100 mg once daily for 5 weeks.
Drug: Clofazimine (CFZ)
Administered orally once daily

Drug: Rifapentine (RPT)
Administered orally once daily

Drug: Isoniazid (INH)
Administered orally once daily

Drug: Pyrazinamide (PZA)
Administered based on weight orally once daily

Drug: Ethambutol (EMB)
Administered based on weight orally once daily

Dietary Supplement: Pyridoxine (vitamin B6)
All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.

Active Comparator: Arm 2: Standard of care for drug-susceptible (DS) TB
Participants will receive rifampicin/isoniazid/pyrazinamide/ethambutol (RHZE) for 8 weeks; then rifampicin/isoniazid (RH) for 18 weeks.
Drug: Isoniazid (INH)
Administered orally once daily

Drug: Pyrazinamide (PZA)
Administered based on weight orally once daily

Drug: Ethambutol (EMB)
Administered based on weight orally once daily

Drug: Rifampicin (RIF)
Administered orally once daily

Dietary Supplement: Pyridoxine (vitamin B6)
All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.

Experimental: Arm C: PK only subgroup
Participants will receive PHZE + CFZ 100 mg once daily for 4 weeks; then on study, off study medications and treated according to SOC (RHZE for 4 weeks; then RH for 18 weeks).
Drug: Clofazimine (CFZ)
Administered orally once daily

Drug: Rifapentine (RPT)
Administered orally once daily

Drug: Isoniazid (INH)
Administered orally once daily

Drug: Pyrazinamide (PZA)
Administered based on weight orally once daily

Drug: Ethambutol (EMB)
Administered based on weight orally once daily

Drug: Rifampicin (RIF)
Administered orally once daily

Dietary Supplement: Pyridoxine (vitamin B6)
All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.




Primary Outcome Measures :
  1. Time to stable culture conversion in liquid media [ Time Frame: Measured through Week 12 ]
    Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB

  2. Proportion of participants across study arms experiencing any Grade 3 or higher adverse event (AE) that is at least a one grade increase from baseline [ Time Frame: Measured through Week 65 ]
    Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, July 2017


Secondary Outcome Measures :
  1. Proportion of participants with favorable clinical/bacteriologic outcome [ Time Frame: Measured at Week 65 ]
  2. Proportion of participants with favorable composite outcome including treatment completion [ Time Frame: Measured at Week 65 ]
  3. Proportion of participants across study arms who prematurely discontinue their treatment regimen [ Time Frame: Measured through Week 65 ]
    Defined as discontinuation other than due to violent death, natural disaster, or administrative censoring

  4. Mean QTcF change from baseline [ Time Frame: Measured at Weeks 2, 8, and 13 (end of investigational treatment) ]
  5. Occurrence of absolute QTcF ≥480 ms and ≤500 ms, and ≥500 ms at any time during study treatment [ Time Frame: Measured through Week 65 ]
  6. Occurrence of QTcF change from baseline of ≥30 ms and ≤60 ms, and ≥60 ms at any time during study treatment [ Time Frame: Measured through Week 65 ]
  7. Time to stable culture conversion in solid media [ Time Frame: Measured through Week 65 ]
    Defined as the first of two (consecutive or non-consecutive) negative sputum cultures without an intervening positive culture, and/or visits wherein the participant is unable to produce sputum and has no signs of active TB

  8. Proportion of participants with culture conversion across all study arms [ Time Frame: Measured at Weeks 8 and 12 ]
  9. Proportion of participants with one or more serious adverse events (SAEs) [ Time Frame: Measured through Week 65 ]
  10. Time (days) to positivity in liquid culture (MGIT) after start of treatment across study arms [ Time Frame: Measured through Week 65 ]
  11. Change in chest X-ray score from baseline to end of treatment in each Arm (week 13 in Arm 1, week 26 in Arm 2) [ Time Frame: Measured through Week 65 ]
    The chest X-ray will be posterior-anterior. Extent of disease (limited to one lobe or region, unilateral, bilateral, or diffuse) and cavitation status (cavities present [location] or absent) will be documented by validated numerical score for grading chest X-ray in adult smear-positive pulmonary TB (Thorax 2010; 65(10):863-9).

  12. Proportion of participants who have a TB relapse, from end of treatment until Week 65 [ Time Frame: Measured through Week 65 ]
  13. Proportion of participants who have a TB recurrence, from end of treatment until Week 65 [ Time Frame: Measured through Week 65 ]
  14. Pharmacokinetic parameter for CFZ: Minimum concentration (Cmin) [ Time Frame: Measured at Weeks 2 and 13 ]
    Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.

  15. Pharmacokinetic parameter for CFZ: Maximum concentration (Cmax) [ Time Frame: Measured at Weeks 2 and 13 ]
    Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.

  16. Pharmacokinetic parameter for CFZ: Time of Cmax (Tmax) [ Time Frame: Measured at Weeks 2 and 13 ]
    Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.

  17. Pharmacokinetic parameter for CFZ: Area under the concentration curve (AUC0-24h) [ Time Frame: Measured at Weeks 2 and 13 ]
    Estimated using noncompartmental methods applied to concentrations from intensive PK sampling visits at weeks 2 and 13.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

    • At least one sputum specimen positive for M. tuberculosis by molecular TB assay (Xpert) or line probe assay [LPA]) OR
    • At least one sputum specimen positive (1+ or greater) for acid-fast bacilli (AFB) on smear microscopy
    • Note: TB diagnosis for purposes of meeting inclusion criterion can be from a study testing laboratory or from an outside laboratory, as long as it is from a sputum sample collected within 5 days prior to entry.
  • Pulmonary TB diagnosed without known INH resistance (e.g., by LPA) and without known RIF resistance (e.g., by either LPA or Xpert).
  • Aged ≥18 years.
  • Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to entry OR
  • HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection.
  • For participants living with HIV, CD4+ cell count ≥100 cells/mm^3, obtained within 30 days prior to study entry at any network-approved non-US laboratory that is Immunology Quality Assessment (IQA) certified.
  • For participants living with HIV must be currently receiving or planning to initiate antiretroviral therapy (ART) at or before study week 8.
  • A verifiable address or residence readily accessible to facilitate directly observed therapy, and willingness to inform the study team of any change of address during the treatment and follow-up period.
  • The following laboratory values obtained at or within 5 days prior to entry by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs.

    • Serum or plasma alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN)
    • Serum or plasma total bilirubin ≤2.5 times ULN
    • Serum or plasma creatinine ≤2 times ULN
    • Serum or plasma potassium ≥3.5 mEq/L and ≤5.5 mEq/L
    • Absolute neutrophil count (ANC) ≥650/mm^3
    • Hemoglobin ≥7.0 g/dL
    • Platelet count ≥50,000/mm^3
  • For females of reproductive potential, negative serum or urine pregnancy test within 5 days prior to entry by any US clinic or laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or is using a point of care (POC)/CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with Good Clinical Laboratory Practice (GCLP) and participates in appropriate external quality assurance programs.
  • Female participants of reproductive potential must agree not to participate in the conception process (i.e., active attempt to become pregnant, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable nonhormonal method of contraception, as listed below, while on study treatment and for 30 days after stopping study medications.

    • Acceptable forms of contraception include:
    • Condoms
    • Intrauterine device or intrauterine system
    • Cervical cap with spermicide
    • Diaphragm with spermicide
    • Note: Hormonal birth control alone is not acceptable, as it may not be sufficiently reliable in combination with RPT or RIF.
  • Female participants who are not of reproductive potential must have documentation of menopause (i.e., at least 1 year amenorrheic), hysterectomy, or bilateral oophorectomy or bilateral tubal ligation.
  • Documentation of Karnofsky performance score ≥50 within 30 days prior to entry.
  • Documentation of either the presence or absence of advanced disease as determined by chest X-ray within 5 days prior to entry.
  • Ability and willingness of participant to provide informed consent.

Exclusion Criteria:

  • More than 5 days of treatment directed against active TB for the current TB episode preceding study entry.
  • Pregnant or breast-feeding.
  • Unable to take oral medications.
  • Current receipt of clofazimine or bedaquiline or known receipt of clofazamine or bedaquiline at any time in the past.
  • QTcF interval >450 ms for men or >470 ms for women within 30 days prior to entry.
  • Weight <30 kg.
  • Current or planned use within 6 months following enrollment of one or more of the following medications: HIV protease inhibitors, HIV entry and fusion inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (other than EFV), elvitegravir/cobicistat, bictegravir, quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine.
  • Current extrapulmonary TB, in the opinion of the site investigator.
  • Current or history of known personal or family long QT syndrome.
  • Known allergy/sensitivity or any hypersensitivity to components of study TB drugs or their formulation.
  • Active drug, alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Known history of acute intermittent porphyria.
  • Other medical conditions (e.g., severe uncontrolled diabetes, liver or kidney disease, blood disorders, peripheral neuritis, chronic diarrhea) in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04311502


Locations
Layout table for location information
Haiti
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
Port-au-Prince, Haiti, HT-6110
India
Byramjee Jeejeebhoy Medical College (BJMC) CRS
Pune, India, 411001
Malawi
Malawi CRS
Lilongwe, Central, Malawi
Blantyre CRS
Blantyre, Malawi, 1131
South Africa
CAPRISA eThekwini CRS
Durban, Kwa Zulu Natal, South Africa, 4013
Zimbabwe
Milton Park CRS
Harare, Zimbabwe
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Study Chair: John Metcalfe, MD, PhD, MPH University of California, San Francisco
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04311502    
Other Study ID Numbers: ACTG A5362
30148 ( Registry Identifier: DAIDS-ES Registry Number )
First Posted: March 17, 2020    Key Record Dates
Last Update Posted: September 11, 2023
Last Verified: July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data that underlie results in the publication, after deidentification.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.
Access Criteria:
  • With whom?

    • Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
  • For what types of analyses?

    • To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
  • By what mechanism will data be made available?

    • Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
rifapentine
clofazimine
drug-susceptible tuberculosis
tuberculosis treatment shortening
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections
Vitamin B 6
Pyridoxal
Pyridoxine
Rifampin
Rifapentine
Clofazimine
Isoniazid
Pyrazinamide
Ethambutol
Vitamins
Micronutrients
Physiological Effects of Drugs
Vitamin B Complex
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers